2011 Trends to Watch: Pharmaceutical Technology
License Price: US$ 4,740.00
Introduction
In collaboration with analysts from Datamonitor's Healthcare business unit, in this brief Ovum's Pharmaceutical Technology team outlines the key changes in the pharma industry, explains which trends will have the biggest impact, and analyzes the implications and opportunities of these developments for both pharmaceutical companies and providers of technologies and services.
Features and benefits
2011 will be a challenging year for the life sciences industry as a result of the dreaded patent cliff, an increase in drug pricing pressures and heightened regulatory scrutiny on drug safety and pharma's marketing tactics.In response to declining sales and rising R&D costs, the industry is expanding out of the developed markets of US, Europe and Japan, into the emerging markets, particularly China and India. Experiencing tremendous growth already, these emerging markets will not be emerging much longer.2011 brings with it many challenges and opportunities for the life sciences industry, and while several uncertainties remain, one thing is certain: technology will be integral to those hoping to see 2012.
Your key questions answered
Introduction
In collaboration with analysts from Datamonitor's Healthcare business unit, in this brief Ovum's Pharmaceutical Technology team outlines the key changes in the pharma industry, explains which trends will have the biggest impact, and analyzes the implications and opportunities of these developments for both pharmaceutical companies and providers of technologies and services.
Features and benefits
- Gives an overview of the current landscape for the global pharmacuetical and biotechnology industries
- Offers insight into factors driving the life sciences industry’s need for IT and how vendors can help companies overcome market challenges
- Provides strategies to help technology vendors penetrate the life science industry
2011 will be a challenging year for the life sciences industry as a result of the dreaded patent cliff, an increase in drug pricing pressures and heightened regulatory scrutiny on drug safety and pharma's marketing tactics.In response to declining sales and rising R&D costs, the industry is expanding out of the developed markets of US, Europe and Japan, into the emerging markets, particularly China and India. Experiencing tremendous growth already, these emerging markets will not be emerging much longer.2011 brings with it many challenges and opportunities for the life sciences industry, and while several uncertainties remain, one thing is certain: technology will be integral to those hoping to see 2012.
Your key questions answered
- Learn about the top trends in the life science industry in 2011
- Tailor your go-to-market strategy to address critical issues facing pharmaceutical and biotechnology companies
- Identify strategies for expanding business opportunities in the life science industry
SUMMARY
Catalyst
Ovum view
Key messages
BUSINESS TRENDS AND TECHNOLOGY ENABLERS
Several key trends and enablers will influence the life sciences industry in 2011
THE 2011 PATENT CLIFF, DRUG PRICING PRESSURES, AND INCREASED REGULATIONS RESTRICT PHARMA'S GROWTH
The long-dreaded patent cliff of 2011 is finally here
Bad news for branded pharma means good news for generics companies
Surviving the patent cliff requires pharma to have a new innovative vision of CRM
The US health reform, in conjunction with a global healthcare crisis, will escalate drug pricing pressures in 2011
To curb skyrocketing healthcare costs, payers are invoking price cuts and reimbursement restrictions
The right social media strategy can do wonders for a pharma company's reputation
Continued regulatory scrutiny is impacting pharma's everyday way of life
Consumer knowledge will significantly affect pharmacovigilance activities
THE EMERGING MARKETS WILL NOT BE EMERGING MUCH LONGER
With an average CAGR of 12% over the next two years, the burgeoning emerging pharma markets are attractive, but some pitfalls remain
Partnering with a domestic firm is the best way for a multinational company to enter an emerging market
With cost-cutting in mind, outsourcing will continue to increase
CROs will have a significant impact on the transformation of the R&D landscape
Emerging markets are hotspots for outsourcing pharma R&D and manufacturing
IT investment will be essential for growth in the emerging markets
Asia and Russia offer the greatest short- and long-term opportunities for IT vendors
Pharma-specific technology solutions will be crucial to growth
With the Latin American markets starting to boom, IT investment will soon follow
The potential of cloud computing to scale quickly
AS R&D PRIORITIES CHANGE, THE LINE BETWEEN PHARMA AND BIOTECH WILL BLUR EVEN MORE IN 2011
The biotech sector is set to play a greater role in the future of the life sciences industry
Secondary care indications and niche patient populations will drive new drug R&D and sales growth
The high costs of developing a blockbuster drug push pharma towards alternatives
Biotechnology will fuel personalized medicine, but the dream is still a way off
Barriers must be overcome before the potential of personalized medicine is realized
The new R&D model will require the integration of IT into drug discovery
RECOMMENDATIONS
Recommendations for life sciences companies
Adopt a multi-channel CRM to interact with a broader, tech-savvy customer base
Break down organizational and system silos to enable collaboration
Collaborate with the larger research community and technology vendors
With transactional solutions now adopted, the next step is analytics
Recommendations for technology vendors
Target the emerging markets in order to see rapid growth
Focus on IT solutions that enable the shift toward biotech research
Position technology along the pharma lifecycle
Know the pharma company's product pipeline and drug portfolio
APPENDIX
Further reading
Methodology
Author
Ovum Consulting
Disclaimer
Catalyst
Ovum view
Key messages
BUSINESS TRENDS AND TECHNOLOGY ENABLERS
Several key trends and enablers will influence the life sciences industry in 2011
THE 2011 PATENT CLIFF, DRUG PRICING PRESSURES, AND INCREASED REGULATIONS RESTRICT PHARMA'S GROWTH
The long-dreaded patent cliff of 2011 is finally here
Bad news for branded pharma means good news for generics companies
Surviving the patent cliff requires pharma to have a new innovative vision of CRM
The US health reform, in conjunction with a global healthcare crisis, will escalate drug pricing pressures in 2011
To curb skyrocketing healthcare costs, payers are invoking price cuts and reimbursement restrictions
The right social media strategy can do wonders for a pharma company's reputation
Continued regulatory scrutiny is impacting pharma's everyday way of life
Consumer knowledge will significantly affect pharmacovigilance activities
THE EMERGING MARKETS WILL NOT BE EMERGING MUCH LONGER
With an average CAGR of 12% over the next two years, the burgeoning emerging pharma markets are attractive, but some pitfalls remain
Partnering with a domestic firm is the best way for a multinational company to enter an emerging market
With cost-cutting in mind, outsourcing will continue to increase
CROs will have a significant impact on the transformation of the R&D landscape
Emerging markets are hotspots for outsourcing pharma R&D and manufacturing
IT investment will be essential for growth in the emerging markets
Asia and Russia offer the greatest short- and long-term opportunities for IT vendors
Pharma-specific technology solutions will be crucial to growth
With the Latin American markets starting to boom, IT investment will soon follow
The potential of cloud computing to scale quickly
AS R&D PRIORITIES CHANGE, THE LINE BETWEEN PHARMA AND BIOTECH WILL BLUR EVEN MORE IN 2011
The biotech sector is set to play a greater role in the future of the life sciences industry
Secondary care indications and niche patient populations will drive new drug R&D and sales growth
The high costs of developing a blockbuster drug push pharma towards alternatives
Biotechnology will fuel personalized medicine, but the dream is still a way off
Barriers must be overcome before the potential of personalized medicine is realized
The new R&D model will require the integration of IT into drug discovery
RECOMMENDATIONS
Recommendations for life sciences companies
Adopt a multi-channel CRM to interact with a broader, tech-savvy customer base
Break down organizational and system silos to enable collaboration
Collaborate with the larger research community and technology vendors
With transactional solutions now adopted, the next step is analytics
Recommendations for technology vendors
Target the emerging markets in order to see rapid growth
Focus on IT solutions that enable the shift toward biotech research
Position technology along the pharma lifecycle
Know the pharma company's product pipeline and drug portfolio
APPENDIX
Further reading
Methodology
Author
Ovum Consulting
Disclaimer
